2024年9月19日，在英格兰伦敦，Keencare药房（Green Light Group成员）的货架上摆放着药品盒。| Leon Neal/Getty Images 伦敦 — 英国公共支出监督机构正在调查唐纳德·特朗普与英国的药品定价协议的成本，此前六名议会委员会主席呼吁展开调查。
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. | Leon Neal/Getty Images LONDON — Britain’s public spending watchdog is probing the cost of Donald Trump’s drug pricing deal with the U.K., after six parliamentary committee chairs called for an investigation.
“我认识到议会对该安排有高度关注，因此我已指示我的团队就此事进行初步调查，”国家审计署（NAO）署长加雷斯·戴维斯在回应议员关切时表示。
“I recognize that there is significant parliamentary interest in the arrangement, and I have therefore instructed my team to make preliminary enquiries about this matter,” the head of the National Audit Office (NAO), Gareth Davies, said in his response to lawmakers’ concerns.
上个月，六名委员会主席致信国家审计署，敦促该支出监督机构调查英美药品定价协议将花费纳税人多少资金，以及是否具有性价比。
The six committee chairs sent a letter to the NAO last month, urging the spending watchdog to investigate how much the U.K.-U.S. drug pricing deal will cost taxpayers and whether it offers value for money.
该协议规定，英国承诺到2035年将其在创新药物上的支出从GDP的0.3%提高到0.6%，即翻一倍，以换取三年内免税进入美国市场。
The deal saw the U.K. commit to doubling its spending on innovative medicines by 2035 from 0.3% to 0.6% of its GDP, in exchange for three years of tariff-free access to the U.S. market.
政府表示，该协议在当前支出审查期间将花费10亿英镑，且今年预算中不会宣布额外资金。然而，官员们拒绝透露该协议的全部成本，称这么做可能损害国际关系和商业利益。
The government has said the deal will cost £1 billion over the current spending review period, with no additional funding to be announced in the budget this year. However, officials have refused to disclose the deal's full cost, arguing that doing so could harm international relations and commercial interests.
“如果没有涵盖未来几年的全面影响评估，议会和公众将无法充分了解该协议对国家医疗服务体系（NHS）预算和更广泛公共支出的长期影响，”议员们在信中写道。
“Without a comprehensive impact assessment covering future years, parliament and the public are unable to fully understand the long-term implications of the agreement for NHS budgets and wider public expenditure,” the lawmakers wrote.
该信由健康和社会护理委员会主席莱拉·莫兰；科学、创新和技术委员会主席奇·奥努拉；商务和贸易委员会主席利亚姆·伯恩；北爱尔兰事务委员会主席托尼亚·安东尼奥齐；苏格兰事务委员会主席帕特里夏·弗格森；以及威尔士事务委员会主席鲁思·琼斯签署。
The letter was signed by Health and Social Care Committee Chair Layla Moran; Science, Innovation and Technology Committee Chair Chi Onwurah; Business and Trade Committee Chair Liam Byrne; Northern Ireland Affairs Committee Chair Tonia Antoniazzi; Scottish Affairs Committee Chair Patricia Ferguson; and Welsh Affairs Committee Chair Ruth Jones.
戴维斯在回复中写道：“我理解议会对该安排本身的审议有限，且政府没有计划公布成本和收益建模的细节。”
“I understand that there has been limited parliamentary scrutiny of the arrangement itself, and the government has no plans to publish the details of how the costs and benefits have been modelled,” Davies wrote in response.
戴维斯表示，他将在国家审计署完成初步调查后，与委员会主席进行后续跟进。
Davies said that he would follow up with the committee chairs, once the NAO completes its initial enquiries.